Healthcare company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Friday the receipt of tentative approval from the US Food and Drug Administration for the generic version of Mirvaso (brimonidine) topical gel 0.33% for the treatment of rosacea.
The company said it had earlier settled litigation with Galderma Laboratories LP and Nestle Skin Health SA for Mirvaso (brimonidine) topical gel 0.33%.
According to the company, the Mirvaso (brimonidine) topical gel 0.33% is indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.
For the 12 months ending June 2016, the annual market sales for Mirvaso® (brimonidine) topical gel 0.33% were USD31m, concluded the company .
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US